Quantcast

Why MacroGenics Stock Is Soaring Today


What happened

Shares of small-cap cancer specialist MacroGenics (NASDAQ: MGNX) rose by as much as 190.9% in early morning trading today on over 36 times the normal daily volume. The stock is soaring in response to a positive late-stage readout for the company's HER2-positive breast cancer treatment candidate, margetuximab. According to the press release, patients treated with a combination of margetuximab and chemotherapy demonstrated a statistically significant improvement in progression-free survival (PFS) compared to those receiving Roche 's Herceptin plus chemotherapy.

Although the biotech's shares have given back some of the enormous gains from the beginning of today's trading session, MacroGenics stock was still up by whopping 131% as of 11:50 a.m. EST.

Female cancer patient staring out of a window in an all-white room

Image source: Getty Images.

So what

Interestingly enough, MacroGenics shares were actually moving lower heading into this pivotal data readout. Prior to today's enormous jump, for instance, the biotech's stock was down by a noteworthy 12.5% for the year. The core issue was that Wall Street apparently didn't think that margetuximab had much of a chance of besting Roche's all-star cancer drug in this head-to-head matchup. Citi analyst Yigal Nochomovitz downgraded the stock only a few days ago due to concerns that margetuximab would fail to improve PFS in this trial.

Now what

With this positive trial readout in hand, MacroGenics plans on filing for the drug's approval with the U.S. Food and Drug Administration in the second half of this year. And if approved, margetuximab should go on to become a tremendous growth driver for the company in the years ahead. This particular breast cancer market, after all, could be worth as much as $10 billion in annual sales by 2025, according to a report by GlobalData. That amount dwarfs MacroGenics' current market cap of approximately $1 billion -- implying that there could be considerably more upside to come.

10 stocks we like better than MacroGenics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and MacroGenics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of January 31, 2019

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: Personal Finance , Stocks
Referenced Symbols: PFS , MGNX



More from Motley Fool

Subscribe






Motley Fool
Contributor:

Motley Fool

Market News, Investing










Research Brokers before you trade

Want to trade FX?